Skip to main content
SpringerLink
Log in

Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients — a comparison of two oral formulations

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The single-dose and steady state kinetics of morphine given as controlled-release tablets (30 mg every 12 h) and as a solution (15 mg every 6 h) have been compared in 11 cancer patients with chronic pain. The concentrations of morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) were analyzed by HPLC.

There were no significant differences between the tablets and solution in the mean steady state concentrations of morphine, M3G or M6G. The tmax was 3.3 h for the tablets compared to 1.1 h for the solution.

After giving the controlled-release tablets every 12 h there was a significantly higher fluctuation index of the morphine concentrations than after the solution. Urinary recovery at steady state was comparable between the two preparations, with averages of 57% and 47%, respectively.

Thus, no major differences were found in the pharmacokinetics of morphine and its glucuronidated metabolites after 30 mg morphine as controlled-release tablets every 12 h or 15 mg of morphine solution every 6 h, except for a significantly longer tmax and greater fluctuation in morphine concentrations after the controlled-release tablets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Iwamoto K, Klaassen C (1977) The first pass of morphine in rats. J Pharmacol Exp Ther 200: 236–244

    Google Scholar 

  2. Dahlström B, Paalzow L, Segre G, Ågren AJ (1978) Relation between morphine pharmacokinetics and analgesia. J Pharmacokinet Biopharm 5: 41–53

    Google Scholar 

  3. Säwe J, Kager L, Svensson Eng JO, Rane A (1985) Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol 19: 495–501

    Google Scholar 

  4. Säwe J (1985) Morphine and its 3- and 6-glucuronides during chronic oral administration in cancer patients. Adv Pain Res Ther 8: 45–55

    Google Scholar 

  5. Säwe J, Dahlström B, Paalzow L, Rane A (1981) Morphine kinetics in cancer patients. Clin Pharmacol Ther 30: 629–635

    Google Scholar 

  6. Twycross RG (1982) Morphine and diamorphine in the terminally ill patient. Acta Anaesth Scand 74 [Suppl]: 128–134

    Google Scholar 

  7. Hanks GW, Twycross RG, Bliss JM (1987) Controlled release morphine tablets: a double-blind trial in patients with advanced cancer. Anaesthesia 42: 840–844

    Google Scholar 

  8. Welsh J, Stuart JFB, Habeshaw T, Blackie R, Whitehill D, Setanoians A, Milsted RAV, Calman KC (1983) A comparative pharmacokinetic study of morphine sulphate solution and MST Continus® 30 mg tablets in conditions expected to allow steady state drug levels. In: Stuart JF (ed) Methods of morphine estimation in biological fluids and the concept of free morphine. Academic Press, London, pp 9–11

    Google Scholar 

  9. Knudsen J, Mortensen SM, Eikland B, Henriksen H (1985) Morfin-depot-tabletter og konventionelle morfintabletter vid cancersmerter. Ugeskr Laeger 148: 780–784

    Google Scholar 

  10. Savarese JJ, Goldenheim PD, Thomas GB, Kaiko RF (1986) Steady state pharmacokinetics of controlled release oral morphine sulphate in healthy subjects. Clin Pharmacokinet 11: 505–510

    Google Scholar 

  11. Poulain P, Hoskin PJ, Hanks GW, Omar OA, Walker VA, Johnston A, Turner P, Aherne GW (1988) Relative bioavailability of controlled release morphine tablets (MST Continus) in cancer patients. Br J Anaesth 61: 569–574

    Google Scholar 

  12. Svensson Eng J-O, Rane A, Säwe J, Sjöqvist F (1982) Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr 230: 427–432

    Google Scholar 

  13. Svensson Eng J-O (1986) Determination of morphine, morphine-6-glucuronide and normorphine in plasma and urine with high-performance liquid chromatography and electrochemical detection. J Chromatogr 375: 174–178

    Google Scholar 

  14. Lilliefors HW (1967) On the Kolmogorov-Smirnov test for normality with mean and variance unknown. J Am Stat Ass 62: 399–402

    Google Scholar 

  15. Grizzle JE (1965) The two-period change-over design and its use in clinical trials. Biometrics 21: 467–480

    Google Scholar 

  16. Grizzle JE (1974) The two-period change-over design and its use in clinical trials. Biometrics 30: 727

    Google Scholar 

  17. Koch GG (1972) The use of non-parametric methods for the statistical analysis of the two-period change-over design. Biometrics 28: 577–584

    Google Scholar 

  18. Dahlström B, Tamsen A, Paalzow L, Hartvig P (1982) Patient-controlled analgesic therapy. Pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinet 7: 266–279

    Google Scholar 

  19. Säwe J (1984) Oral morphine and methadone in the treatment of cancer pain. Clinical pharmacokinetic studies. Doctoral thesis, Karolinska Institute, Stockholm, Sweden

    Google Scholar 

  20. Vater M, Smith G, Aherne GW, Aitkenhead AR (1984) Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. Br J Anaesth 56: 821–827

    Google Scholar 

  21. Neumann PB, Henriksen H, Grosman N, Christensen CB (1982) Plasma morphine concentrations during chronic oral administration in patients with cancer pain. Pain 13: 247–252

    Google Scholar 

  22. Säwe J, Svensson JO, Rane A (1983) Morphine metabolism in cancer patients on increasing oral doses — no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol 16: 85–93

    Google Scholar 

  23. Kager L, Ljungdahl I, Rane A, Säwe J (1979) Oral morphine treatment of pain in terminal cancer. Läkartidningen 76: 3411–3415

    Google Scholar 

  24. Aherne GW, Piall EM, Twycross RG (1979) Serum morphine concentration after oral administration of diamorphine hydrochloride and morphine sulphate. Br J Clin Pharmacol 8: 577–580

    Google Scholar 

  25. Brunk SF, Delle M (1974) Morphine metabolism in man. Clin Pharmacol Ther 16: 51–57

    Google Scholar 

  26. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K, Yoshimura H, Tsukamoto H (1971) Analgesic effect of morphine glucuronides. Tohoku J Exp Med 105: 45–52

    Google Scholar 

  27. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE (1987) Morphine-6-glucuronide, a potent mu agonist. Life Sci 41: 2845–2849

    Google Scholar 

  28. Osborne R, Joel S, Trew D, Slevin M (1988) Analgesic activity of morphine-6-glucuronide. Lancet I: 828

    Google Scholar 

  29. Osborne RJ, Joel SP, Slevin ML (1986) Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J 292: 1548–1549

    Google Scholar 

  30. Hasselström J, Berg U, Löfgren A, Säwe J (1989) Long lasting respiratory depression induced by morphine-6-glucuronide? Br J Clin Pharmacol 27: 515–518

    Google Scholar 

  31. McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA (1990) Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48: 236–244

    Google Scholar 

  32. Twycross RG (1974) Clinical experience with diamorphine in advanced malignant disease. Int J Clin Pharmacol Ther Toxicol 9: 184–198

    Google Scholar 

  33. Yeh SY (1973) Urinary excretion of morphine and its metabolites in morphine-dependent subjects. J Pharmacol Exp Ther 22: 1423–1430

    Google Scholar 

  34. Dahlström B, Paalzow L (1978) Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat. J Pharmacokinet Biopharm 6: 505–519

    Google Scholar 

  35. Shepard TA, Reuning RH, Aarons LJ (1985) Estimation of area under the curve for drugs subject to enterohepatic cycling. J Pharmacokinet Biopharm 13: 589–608

    Google Scholar 

  36. Karnofsky DA, Abelman WH, Craver LF, Burchenal JH (1948) The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634–656

    Google Scholar 

  37. Osborne R, Joel S, Trew D, Slevin M (1990) Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47: 12–19

    Google Scholar 

  38. Weitz CJ, Faull KF, Goldstein A (1987) Synthesis of the skeleton of the morphine molecule by mammalian liver. Nature 330: 674–677

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden

    J. Hasselström, J. O. Svensson & J. Säwe

  2. Department of Pulmonary Medicine, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden

    C. Bringel

  3. Pharmacia AS, Hillerød, Denmark

    N. Alexander

Authors
  1. J. Hasselström
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Bringel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. O. Svensson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Säwe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hasselström, J., Alexander, N., Bringel, C. et al. Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients — a comparison of two oral formulations. Eur J Clin Pharmacol 40, 585–591 (1991). https://doi.org/10.1007/BF00279975

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00279975

Key words

Search

Navigation